Xavier Gitton

Xavier Gitton

Main Specialties: Obstetric Anesthesiology, Oral Medicine, Pain Medicine, Pediatric Anesthesiology, Pediatric Rheumatology, Public Health, Sleep Medicine

Xavier Gitton

Xavier Gitton

Publications

13Publications

388Reads

2Profile Views

Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.

BMC Musculoskelet Disord 2011 Jul 7;12:153. Epub 2011 Jul 7.

Department of Internal Medicine II, Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Heubnerweg, Berlin 14059, Germany.

View Article

Download full-text PDF

Source
http://bmcmusculoskeletdisord.biomedcentral.com/articles/10.
Publisher Site
http://dx.doi.org/10.1186/1471-2474-12-153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152943PMC
July 2011
59 Reads
1.898 Impact Factor

Use of canakinumab in the cryopyrin-associated periodic syndrome.

N Engl J Med 2009 Jun;360(23):2416-25

University College London Medical School, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa0810787DOI Listing
June 2009
52 Reads
55.873 Impact Factor

A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.

J Clin Hypertens (Greenwich) 2008 Aug;10(8):592-602

Clinical Trials Unit, Mount Sinai Cardiovascular Institute, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1751-7176.2008.07802.xDOI Listing
August 2008
11 Reads
2.958 Impact Factor

Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.

J Womens Health (Larchmt) 2008 Apr;17(3):423-37

Scirex Clinical Research Centers, Austin, TX 78705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jwh.2007.0416DOI Listing
April 2008
51 Reads
1.896 Impact Factor

Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.

Gastroenterology 2007 Jul 27;133(1):57-64. Epub 2007 Apr 27.

Wolfson Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S001650850700831
Publisher Site
http://dx.doi.org/10.1053/j.gastro.2007.04.045DOI Listing
July 2007
25 Reads
16.716 Impact Factor

Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.

Clin Gastroenterol Hepatol 2006 Jan;4(1):57-66

Wolfson Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1542-3565(05)00976-6DOI Listing
January 2006
9 Reads
7.896 Impact Factor

Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.

Curr Med Res Opin 2005 Jan;21(1):151-61

Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/030079904x20231DOI Listing
January 2005
10 Reads
2.653 Impact Factor

Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.

J Rheumatol 2004 Sep;31(9):1804-10

University Hospital Nottingham, Nottingham, United Kingdom.

View Article

Download full-text PDF

Source
September 2004
25 Reads
3.187 Impact Factor